Global Information would like to present a market research report, "Regenerative Medicines: Bone and Joint Applications" by BCC Research.
Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2 billion in economic activity in 2009. Bone and joint applications account for a little more than half of those revenues, or $1.2 billion. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003. In addition, intensive R&D efforts at universities and the National Institutes of Health that focus on cutting-edge technology underscore the importance of this industry.
The key objective of regenerative medicine is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and particularly biomedical engineering. The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important. Stem-cell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinal-cord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.